---
schema_version: "secwatch.filing_event.v1"
accession: "0001818382-25-000030"
form_type: "8-K"
ticker: "HUMA"
cik: "0001818382"
company_name: "Humacyte, Inc."
filed_at: "2025-03-28T23:59:59+00:00"
generated_at: "2026-05-24T03:13:44.340050+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Humacyte posts Q4 net loss of $20.9M; Symvess commercial launch underway after FDA approval

## Summary
- Net loss Q4 2024 $20.9M vs $25.1M Q4 2023; full year net loss $148.7M vs $110.8M.
- Cash $95.3M at Dec 31, 2024; raised $46.6M net in March 2025 public offering.
- FDA approved Symvess Dec 19, 2024 for extremity vascular trauma; first commercial shipments to two Level 1 trauma centers in Feb 2025.
- 34 hospitals started VAC approval process; 3 approved; first sales recorded.
- R&D expenses $88.6M in 2024 (up 16% YoY); no revenue in period.

## SEC filing metadata
- accession: 0001818382-25-000030
- form_type: 8-K
- ticker: HUMA
- cik: 0001818382
- company_name: Humacyte, Inc.
- filed_at: 2025-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818382/000181838225000030/0001818382-25-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818382/000181838225000030/huma-20250328.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001818382-25-000030
- JSON: https://secwatch.observer/filing/0001818382-25-000030.json
- Plain text: https://secwatch.observer/filing/0001818382-25-000030.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.